UNSPSC 51291803: Moclobemide

This classification denotes a monoamine oxidase inhibitor with the molecular formula C13H17ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PJ0Y7AZB63, chemically known as benzamide, 4-chloro-n-(2-(4-morpholinyl)ethyl)- but generally known as moclobemide, which bears US NIH Compound Identifier 4235. European Medicines Agency schedules Moclobemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09024MIG.

UNSPSC 51291803 Moclobemide is a Commodity code for a specific antidepressant pharmaceutical product. State and local governments buy moclobemide primarily through broader pharmaceutical procurement frameworks that aggregate multiple drug products rather than as a standalone line item. The solicitations tagged under this code show state and local health agencies and cooperative purchasing alliances sourcing generic pharmaceuticals and over-the-counter products, including drugs used to address opioid-related emergencies and mental health needs, though moclobemide itself does not appear explicitly in the recent opportunity descriptions. Issuing bodies include state health and human services commissions, county health departments, and multistate cooperative purchasing consortia. The scope of work spans annual supply agreements with manufacturers and authorized wholesalers, quarterly or on-demand delivery to health facilities, compliance with FDA and Drug Supply Chain Security Act requirements, and fixed or negotiated pricing structures with administrative fee arrangements.

Recent activity appears concentrated in Florida, Texas, and the Upper Midwest cooperative purchasing jurisdictions, with Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP) administering a multistate RFP for generic pharmaceuticals and OTC products with responses due March 26, 2026 and an effective contract date of July 1, 2026. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The MMCAP RFP requires vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), meet cGMP and DSCSA compliance standards, and accept a 3 percent administrative fee, with price competitiveness weighted at 75 percent of evaluation scoring.